Cargando…

Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma

S100 proteins are involved in carcinogenesis, metastasis, and survival. S100A2 is a member of the S100 family, and its expression and precise role in patients with non-small cell lung carcinoma (NSCLC) has been debated. Therefore, we examined the immunohistochemical expression patterns of S100A2 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hountis, Panagiotis, Foukas, Periklis G, Matthaios, Dimitrios, Kefala, Maria, Chelis, Leonidas, Pantelidaki, Aikaterini, Panayiotides, Ioannis G, Karakitsos, Petros, Kakolyris, Stylianos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507318/
https://www.ncbi.nlm.nih.gov/pubmed/23189031
http://dx.doi.org/10.2147/OTT.S36474
_version_ 1782251059529383936
author Hountis, Panagiotis
Foukas, Periklis G
Matthaios, Dimitrios
Kefala, Maria
Chelis, Leonidas
Pantelidaki, Aikaterini
Panayiotides, Ioannis G
Karakitsos, Petros
Kakolyris, Stylianos
author_facet Hountis, Panagiotis
Foukas, Periklis G
Matthaios, Dimitrios
Kefala, Maria
Chelis, Leonidas
Pantelidaki, Aikaterini
Panayiotides, Ioannis G
Karakitsos, Petros
Kakolyris, Stylianos
author_sort Hountis, Panagiotis
collection PubMed
description S100 proteins are involved in carcinogenesis, metastasis, and survival. S100A2 is a member of the S100 family, and its expression and precise role in patients with non-small cell lung carcinoma (NSCLC) has been debated. Therefore, we examined the immunohistochemical expression patterns of S100A2 in NSCLC in relation to clinicopathological parameters, important molecular biomarkers, and patient outcome. Microarray data for 74 paraffin-embedded specimens from patients with NSCLC were immunostained for S100A2 and p53 proteins. Immunohistochemical staining patterns of S100A2 in the NSCLC tissue samples examined were either nuclear (nS100A2), cytoplasmic (cS100A2), or both. A significant association between nS100A2 positivity and better disease-free interval was observed (hazards ratio 0.47; 95% confidence interval 0.23–0.99; P = 0.047). Similarly, cS100A2 negativity was marginally associated with shorter overall survival (P = 0.07). Patients without lymphatic infiltration and an earlier disease stage had significantly better overall survival and disease-free interval. The S100A2 expression pattern in operable NSCLC varies widely, and this differential expression (nuclear, cytoplasmic or both) seems to correlate with prognosis. Intensity of expression was highest in the early and advanced stages, and equally distributed in the middle stages. This observation may be indicative of a dual role for this protein both during earlier and advanced disease stages, and may also explain the differential immunoexpression of S100A2. Analysis of the disease-free interval showed that nS100A2-negative and p53-positive expression was associated with a statistically significant (P = 0.003) shorter disease-free interval in comparison with nS100A2-positive and p53-negative expression (12 versus 30 months, respectively). Further studies are required to establish whether S100A2 protein may have a substantial role as a prognostic or predictive indicator in this unfavorable group of patients.
format Online
Article
Text
id pubmed-3507318
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35073182012-11-27 Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma Hountis, Panagiotis Foukas, Periklis G Matthaios, Dimitrios Kefala, Maria Chelis, Leonidas Pantelidaki, Aikaterini Panayiotides, Ioannis G Karakitsos, Petros Kakolyris, Stylianos Onco Targets Ther Original Research S100 proteins are involved in carcinogenesis, metastasis, and survival. S100A2 is a member of the S100 family, and its expression and precise role in patients with non-small cell lung carcinoma (NSCLC) has been debated. Therefore, we examined the immunohistochemical expression patterns of S100A2 in NSCLC in relation to clinicopathological parameters, important molecular biomarkers, and patient outcome. Microarray data for 74 paraffin-embedded specimens from patients with NSCLC were immunostained for S100A2 and p53 proteins. Immunohistochemical staining patterns of S100A2 in the NSCLC tissue samples examined were either nuclear (nS100A2), cytoplasmic (cS100A2), or both. A significant association between nS100A2 positivity and better disease-free interval was observed (hazards ratio 0.47; 95% confidence interval 0.23–0.99; P = 0.047). Similarly, cS100A2 negativity was marginally associated with shorter overall survival (P = 0.07). Patients without lymphatic infiltration and an earlier disease stage had significantly better overall survival and disease-free interval. The S100A2 expression pattern in operable NSCLC varies widely, and this differential expression (nuclear, cytoplasmic or both) seems to correlate with prognosis. Intensity of expression was highest in the early and advanced stages, and equally distributed in the middle stages. This observation may be indicative of a dual role for this protein both during earlier and advanced disease stages, and may also explain the differential immunoexpression of S100A2. Analysis of the disease-free interval showed that nS100A2-negative and p53-positive expression was associated with a statistically significant (P = 0.003) shorter disease-free interval in comparison with nS100A2-positive and p53-negative expression (12 versus 30 months, respectively). Further studies are required to establish whether S100A2 protein may have a substantial role as a prognostic or predictive indicator in this unfavorable group of patients. Dove Medical Press 2012-11-21 /pmc/articles/PMC3507318/ /pubmed/23189031 http://dx.doi.org/10.2147/OTT.S36474 Text en © 2012 Hountis et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Hountis, Panagiotis
Foukas, Periklis G
Matthaios, Dimitrios
Kefala, Maria
Chelis, Leonidas
Pantelidaki, Aikaterini
Panayiotides, Ioannis G
Karakitsos, Petros
Kakolyris, Stylianos
Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma
title Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma
title_full Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma
title_fullStr Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma
title_full_unstemmed Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma
title_short Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma
title_sort prognostic significance of different immunohistochemical s100a2 protein expression patterns in patients with operable nonsmall cell lung carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507318/
https://www.ncbi.nlm.nih.gov/pubmed/23189031
http://dx.doi.org/10.2147/OTT.S36474
work_keys_str_mv AT hountispanagiotis prognosticsignificanceofdifferentimmunohistochemicals100a2proteinexpressionpatternsinpatientswithoperablenonsmallcelllungcarcinoma
AT foukasperiklisg prognosticsignificanceofdifferentimmunohistochemicals100a2proteinexpressionpatternsinpatientswithoperablenonsmallcelllungcarcinoma
AT matthaiosdimitrios prognosticsignificanceofdifferentimmunohistochemicals100a2proteinexpressionpatternsinpatientswithoperablenonsmallcelllungcarcinoma
AT kefalamaria prognosticsignificanceofdifferentimmunohistochemicals100a2proteinexpressionpatternsinpatientswithoperablenonsmallcelllungcarcinoma
AT chelisleonidas prognosticsignificanceofdifferentimmunohistochemicals100a2proteinexpressionpatternsinpatientswithoperablenonsmallcelllungcarcinoma
AT pantelidakiaikaterini prognosticsignificanceofdifferentimmunohistochemicals100a2proteinexpressionpatternsinpatientswithoperablenonsmallcelllungcarcinoma
AT panayiotidesioannisg prognosticsignificanceofdifferentimmunohistochemicals100a2proteinexpressionpatternsinpatientswithoperablenonsmallcelllungcarcinoma
AT karakitsospetros prognosticsignificanceofdifferentimmunohistochemicals100a2proteinexpressionpatternsinpatientswithoperablenonsmallcelllungcarcinoma
AT kakolyrisstylianos prognosticsignificanceofdifferentimmunohistochemicals100a2proteinexpressionpatternsinpatientswithoperablenonsmallcelllungcarcinoma